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HEART TRANSPLANTATION 
The CliniCal Trial of FK 506 as Primary and Rescue 
Immunosuppression in Adult Cardiac Transplantation 
J.M. Armitage, R.L. Kormos, J. Fung, and T.E. Starzl 
FK 506. a potent immunosuppressive macrolide antibi-
otic. has undergone clinical testing at the Presbyte-
rian University Hospital since January 1989. The initial 
clinical trials were directed at liver transplant recipients 
with refractory rejection. 1.2 and pursuant to these dramatic 
and gratifying results FK 506 was introduced as primary 
immunosuppression in kidney and liver recipients in 
March 1989.3.4 Ever since October 1989. in a prospective 
clinical trial. 61 patients have undergone orthotopic car-
diac transplantation with FK 506 and low-dose steroids as 
primary immunosuppression. Dramatic results were also 
attained in eight patients with cardiac rejection refractory 
to all known conventional treatment and who underwent 
rescue therapy with FK 506. 
METHODS 
Patient Group 
Sixty-one patients were prospectively entered into this study from 
October 1989 to August 1991. Informed consent was obtained 
from each patient prior to transplantation for the use of FK 506 
and steroids as the sole immunosuppressive therapy; six patients 
received conventional cyclosporine-based immunosuppressiOn 
during this penod. 
In the sludy group were 53 males and 8 females (age range 1810 
61 years). Seven patients 01%) required mechanical circulatory 
suppon prior to transplantation in the form of the Novacor Left 
Ventricular Assist Device (LVAD) (5). Thoratec LV AD (I). and 
Total Anificial Hean (I). Six other patients awaited transplanta-
tion with intra-aonic balloon pump HABP) suppon. The etiology 
of cardiomyopathy included ischemic (30). idiopathic (18). valvu-
lar (3). myocarditis (3). hypenrophic (3) and retransplantation (4). 
Median follow-up of these 61 patients was 260 days (range 15-670 
days) as of August 1991. No attempt was made to enroll patients 
selectively in this study based on severity of illness or preopera-
tive status. 
Eight adult pallents who had cardiac rejection refractory to 
convenllonal immunosuppressive treatment were treated with FK 
506 rescue therapy. Four of these patients were referred to our 
institullon from olher centers. 
FK 506 Therapy 
FK 506 was administered intravenously for 24 to 72 hours after 
cardiac transplantalJon at a dose of 0.07S/mglka per day in two 
divided doses. Oral FK S06 was begun 24 hours after transplan-
tation. The oral maintenance dose of FK 506 required to attain a 
level of I to U nglmL 02 hour through serum ELISA by the 
technique of Temura).!; it ranged from 0.2 to 0.4 mg/kg per day. 
Methylprednisolone. 7 mgikg. was administered intravenously in 
the operating room and 5 mgikg postoperatively for 24 houn in 
three divided doses. Thereafter. patients received O.IS mglkg per 
day prednisone orally once a day. Prednisone was then tapered 
and discontinued based on rejection history. 
Other Agents 
All patients entered into the FK 506 immunotherapy protocol 
were placed on prophylactic oral trimethoprimlsulfamethoxazole. 
acyclovir. and Mycostatin. 
Monitoring for Rejection 
Posttransplant surveillance on all patients involved weekly trans-
venous endomyocardial biopsies during hospitalization and at 
slowly increased intervals after discharge. Biopsies were graded 
using hematoxylin and eosin staining after light microscopy by a 
pathologist who was blinded to the immunosuppressive protocol 
of the patient. Biopsy grades were defined according to a modified 
Billingham scale. Rejection was defined by the presence of 
myocyte necrosis in association with an interstitial lymphocytic 
infiltrate (grade 3 or moderate rejection) or with hemorrhage 
(grade 4 or severe rejection). 
Monitoring for Infection 
All patients were followed by an infectious-disease specialist. 
Pretransplant titers for hepatitis B. herpes virus, Epstein-Barr 
virus (EBV). human immunodeficiency virus (HIV). Toxoplasma, 
and cytomegalovirus (CMV) were performed on all donon and 
recipients. The diagnosis of infection was made using clinical 
criteria as previously defined by this institution. b Complete blood 
screening was performed daily in the hospital and at all follow-up 
visits. Questionnaires to identify untoward side ellects of FK S06 
were completed on all patients. 
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RESULTS 
Survival 
Fifty-six (92%) of 61 patients entered into this trial are 
alive. The earliest death occurred on the fourth postoper-
ative day secondary to pulmonary hypertension and right-
heart failure. Two other deaths occurred at 30 and 54 days 
from causes unknown: neither of these latter two patients 
had any episode of rejection. One patient died of sudden 
death at home on an exercise cycle and permission was 
denied for postmortem examination. The other patient 
died of low cardiac output. the etiology of which remains 
unclear despite complete postmortem examination: no 
evidence of cellular or humoral rejection was evident in the 
heart. Two late deaths have occurred. one due to infection 
and one due to coronary occlusion. No mortality has been 
attributed to FK 506 therapy or to acute or refractory 
cardiac rejection. 
Rejection 
At 3 months posttransplant there were 48 episodes of grade 
JA rejection in 61 patients. Beyond 3 months few episodes 
of rejection have occurred. The episodes of grade 3A 
rejection at 90 days in this study were 0.8 per patient (n = 
53). The actuarial freedom from rejection at 3 months was 
40% and remained so at 6 and 9 months. 
Rejection episodes of moderate severity (Billingham 
criteria 3A) were preferentially treated by increased doses 
of FK 506. 4 to 8 mg/d in the adult patients. Moderate or 
severe rejection (Billingham criteria 3 B or 4) was treated 
either by intravenous methylprednisolone. 1 g for 24 or 48 
hours. or with a short-course oral prednisone taper. 100 mg 
to 20 mg over 5 days. in those patients whose FK 506 
levels were already in the high therapeutic range or in 
whom azotemia (BUN >50 and creatinine >2.0) limited 
further manipulation of FK S06 therapy. 
Eight patients have reqUired the addition of azathioprine 
to their immunosuppressive regimen and three patients 
have required treatment with OKT3 for severe rejection. 
Infection 
Three major infections in two patients were present prior 
to cardiac transplantation. One patient had two pretrans-
plant infections: staphylococcal line sepsis secondar y to an 
IABP. and a positive sternal wound culture for candida at 
the time of Novacor LV AD removal. This same patient 
had pulmonary emboli and infarctions yet remained free of 
infection posttransplant managed on FK 506 as his sole 
Immunosuppressive agent. Amphotericin was adminis-
tered for 5 weeks after transplantation and the patient 
recovered without sequelae. The other patient with a 
rretransplant infection had a Klebsiella pneumonia during 
lABP support. which had been treated for M days when a 
donor heart became available. This patient recovered 
without further Infection. 
At posttransplant there were 16 infections in 14 of 61 
patients on pnmary FK S06 therapy. No patient in the 
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rescue group had a diagnosed infection. There were six 
(10%) m~or infections in four patients. which consisted of 
three pneumonias. one pulmonary abscess. one Clostridia 
difficile colitis. and one abdominal wall and mediastinal 
infection after Novacor LV AD. There were 10 (16%) 
minor infections. Freedom from major infection in the 
primary FK 506 group at the median follow-up of 260 days 
was 90%. 
Cardiac Function 
All surviving patients enjoy excellent cardiac function. 
The average left ventricular ejection fraction (LVEF) in 
the group measured by gated nuclear scan and/or echocar-
diography was 66%. The range of L VEF was 48% to 75% 
at the time of longest follow-up. 
Renal Function and Hypertension 
In 53 patients followed for greater than 90 days the average 
serum creatinine prior to transplant was 1.2 ng/dL. When 
FK 506 was administered intravenously at a dose of 0.15 
mglkg per day infused either as bolus therapy twice a day 
or as a continuous 24-hour infusion there was associated 
nephrotoxicity. Three patients (5%) required dialysis in the 
perioperative period: however. renal function returned 
near baseline within 7 to 10 days. One patient who required 
dialysis suffered a cardiac arrest on induction to anesthesia 
and had an IABP inserted: these events were associated 
with mild hepatic dysfunction and FK 506 levels greater 
than 20 ng/mL in the early posttransplant period. Since IV 
induction FK 506 has been changed to a continuous 
infusion dose of 0.075 mg/kg per day for 24 hours. acute 
renal dysfunction. whkh required dialysis. has not been 
observed. Excluding these three patients who required 
dialysis. peak renal dysfunction occurred at the first post-
operative week. and the average serum creatinine was 2.6 
ngJdL (standard deviation 1.(3). This peak renal dysfunc-
tion was associated with an average FK S06 level of S.I 
ng/mL (mnge 0.8-12 ng/mLl. The average serum creati-
nine at 3 months follow-up was 1.% ng/dL (standard 
deviation 0.86) and was attained by most patients by the 
second postoperative week. A verage serum creatinine at 6 
months was 2.2 ng/dL. 
Hypertension is rare in patients following cardiac trans-
plantation treated with FK 506 and low-dose steroids. 
Only 22 patients (39%) followed for greater than 3 months 
have required antihypertensive treatment and all are well 
controlled on a single agent. 
Cardiac Rescue Therapy 
Eight patients who suffered from cardiac rejection refrac-
lOry to aggressive conventional immunotherapy were 
treated with FK 506. All of these patients had been treated 
With cyclosporine (eyA). azathiopnne. and steroids: all 
had received two or more courses of intravenous steroids 
and one or more courses of antilymphocyte therapy 
(RATG. Minnesota ALG. or OKT3) and had persistent 
rejection. 
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The rescue patients have tolerated the switch from Cy A 
to FK 506 without significant complications. Cyclosporine 
was discontinued 24 to 48 hours prior to FK 506 induction. 
No loading dose of FK 506 was administered. The patients 
were begun on oral FK 506, 0.3 mglkg per day, in two 
divided doses. Azathioprine was discontinued and steroids 
were given at half the maintenance dose. Pending improve-
ment in subsequent patient biopsies. steroids were tapered 
and all eight patients are on one-quarter their previous 
prednisone dose. All patients have either resolved or 
significantly improved the histologic endomyocardial bi-
opsy grading of rejection. 
Two FK 506 rescue patients complained of muscle and 
joint aches and lower limb paresthesias for the first few 
weeks following the switch in therapy. These have all 
resolved. Presumably. these symptoms were related to 
Cy AlFK 506 interactions as they have not been observed 
in primary FK 506 patients. Renal function has remained 
normal in all rescue patients. 
Metabolic Studies and Side Effects 
There were II insulin-dependent diabetics in the 56 pa-
tients on primary FK 506 therapy following cardiac trans-
plantation. Four of these 11 diabetics were insulin depen-
dent prior to transplantation. There were seven new-onset 
diabetic patients of 52 nondiabetic recipients (13.4%). All 
of the new-onset diabetics were also on prednisone (aver-
age dose 7 mgld). 
Continued monitoring of hematologic and coagulation 
indices. as well as hepatic function. failed to reveal any 
abnormalities in our patients at this follow-up interval. 
Cholesterol and triglycerides have been slightly lower than 
those in Cy A-treated patients: however. this is not statis-
tically significant. Four patients have borderline elevated 
uric acid levels. Slightly elevated serum potassium levels 
have also been observed in some patients. independent of 
renal dysfunction. and we have avoided the exogenous 
administration of potassium in this group unless specifi-
cally indicated (serum K" < 3.5 mEq/L). 
Side elfects have been rare despite routine question-
naires during hospitalization and during outpatient follow-
up. There have been no seizures. cerebrovascular acci-
dents (CV AI. or neuropathies secondary to FK 506. One 
patient in the primary therapy group had a thromboem-
bolic occipital CV A with associated hemorrhage and sei-
zure from which he has recovered with little residual 
deficit. There have been occasional reports. of extremity 
paresthesia and temperature malsensations usually associ-
ated with elevated FK 506 levels. One patient with mild 
multiple sclerosis developed akinetic mutism on FK 506. 
which required reduction in dosing; however. he has since 
recovered and returned to work. Muscle aches and mild 
insomnia were also reported rarely. Notably absent in this 
patient group were complaints of gingival hyperplasia. 
tremor. or hirsutism. 
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DISCUSSION 
These preliminary results with FK 506 and low-dose 
steroid immunosuppression hold tremendous promise for 
the future, as both primary immunotherapy in cardiac 
transplantation and as an effective agent for rescue therapy 
in refractory cardiac rejection. In a prospective random-
ized study performed at the University of Pittsburgh. 
comparing RATG to OKTI immunoprophylaxis. with 
Cy A-based triple drug therapy, the OKT3 immunoprophy-
lax is group had an actuarial freedom from rejection at 90 
days posttransplant of 40% with 1.0 episode of rejection 
per patient. 7 The actuarial freedom from rejection in the 
FK 506 and low-dose steroid immunotherapy group at 90 
days posttransplant is 40% with 0.80 episodes of rejection 
per patient. We have been impressed with the ability of 
this new agent to attain comparable immunosuppression in 
cardiac transplant recipients to one of the best immuno-
suppressive protocols at the University of Pittsburgh dur-
ing the last decade. This level of immunosuppression has 
been achieved without antilymphocyte therapy, without 
immunoprophylaxis. without azathioprine. and with 
marked reduction in steroid requirement. Seventeen of the 
56 patients in this study are on no steroids at all. The 
average steroid dose in the adults is 8.6 mg of prednisonel 
patient. The ability of FK 506 to reverse cardiac rejection 
that has been refractory to aggressive treatment with 
conventional immunotherapeutic tools. along with the 
relatively low rate of major (11%) and minor (16%) infec-
tions. is further testament to the potency and selectivity of 
its immunosuppressive actions. Another added advantage 
of FK 506 is the flexibility it introduces to immunosuppres-
sive management. Mild to moderate rejection. which oc-
curred in the first 3 months posttransplant. was treated by 
merely increasing the FK 506 dose. The concept of aug-
menting immunosuppression and treating rejection by in-
creasing baseline immunotherapy adds a new tool to our 
armamentarium of antirejection therapy. The biologic and 
immunologic basis for this quality of FK 506 is presently 
under intense study at the University of Pittsburgh. 
Despite the excellent tolerance of FK 506 by patients. 
and few observed or reported side elfects. renal dysfunc-
tion is a price paid when the drug is used as described in 
this report. We believe that systematic overdosing has 
occurred in patients receiving FK 506 intravenously in the 
perioperative period in our attempt to achieve high early 
FK 506 levels. We have changed initial bolus intravenous 
FK 506 therapy to continuous infusion. and now. more 
recently. we have lowered the initial IV dose to a single 
24-hour constant-infusion dose at 0.075 mg/kg. with enteral 
FK 506 begun on the first postoperative day. When reduc-
tion or elimination of the postoperative I V loading dose of 
FK 506 was attempted. the time to the first grade 3 
rejection was diminished to 22 days. We feel that the IV 
induction dose is important to gam appropriate early 
up-regulation of the immune system. Further refinements 
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in our knowledge regarding FK S06 dosing and therapeutic 
levels, together with the diminished incidence of hyperten-
sion, may actually improve the long-term outlook for renal 
function in cardiac transplant recipients. When compared 
to the 40 cardiac transplant recipients transplanted at the 
University of PittsbUl'lh before October 1989. the inci-
dence of hypertension was 70% as opposed to 38% in the 
FK S06 group (P < .01). Twenty annual catheterizations 
have been perfonned, none of which revealed coronary 
disease. 
Both cardiac function and the quality of life8 in our small 
patient group have been excellent. Concerns regarding 
vasculitis and neuropathy have not been realized. The 
benefit of steroid sparing, lack of nonspecific bone marrow 
suppression. and antilymphocyte and antihypertensive 
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therapy hold tremendous promise for the future of cardiac 
transplant recipients. 
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